Ind-Swift Limited (INDSWFTLTD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ind-Swift Limited (INDSWFTLTD) has a cash flow conversion efficiency ratio of -0.039x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs158.56 Million ≈ $1.71 Million USD) by net assets (Rs-4.02 Billion ≈ $-43.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ind-Swift Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Ind-Swift Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read INDSWFTLTD current and long-term liabilities for a breakdown of total debt and financial obligations.
Ind-Swift Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ind-Swift Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
|
N/A |
|
Pioneer Lithium Ltd
AU:PLN
|
N/A |
|
Thai Coating Industrial Public Company Limited
BK:TCOAT
|
-0.006x |
|
Kwang Jin Ind. Co. Ltd
KQ:026910
|
0.049x |
|
Bekasi Asri Pemula Tbk
JK:BAPA
|
-0.003x |
|
Pioneer Embroideries Limited
NSE:PIONEEREMB
|
0.057x |
|
Venzee Technologies Inc
V:VENZ
|
-0.012x |
|
Ta Win Holdings Bhd
KLSE:7097
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Ind-Swift Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Ind-Swift Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Ind-Swift Limited market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs-4.02 Billion ≈ $-43.51 Million |
Rs158.56 Million ≈ $1.71 Million |
-0.039x | -78.15% |
| 2024-03-31 | Rs-6.91 Billion ≈ $-74.71 Million |
Rs152.83 Million ≈ $1.65 Million |
-0.022x | +78.66% |
| 2023-03-31 | Rs-7.05 Billion ≈ $-76.21 Million |
Rs730.46 Million ≈ $7.90 Million |
-0.104x | -48.73% |
| 2022-03-31 | Rs-7.20 Billion ≈ $-77.90 Million |
Rs502.02 Million ≈ $5.43 Million |
-0.070x | +41.76% |
| 2021-03-31 | Rs-6.95 Billion ≈ $-75.18 Million |
Rs831.93 Million ≈ $9.00 Million |
-0.120x | -146.68% |
| 2020-03-31 | Rs-7.13 Billion ≈ $-77.12 Million |
Rs345.96 Million ≈ $3.74 Million |
-0.049x | +23.32% |
| 2019-03-31 | Rs-6.76 Billion ≈ $-73.14 Million |
Rs427.86 Million ≈ $4.63 Million |
-0.063x | -485.49% |
| 2018-03-31 | Rs-6.63 Billion ≈ $-71.72 Million |
Rs71.66 Million ≈ $774.98K |
-0.011x | -486.50% |
| 2017-03-31 | Rs-6.16 Billion ≈ $-66.56 Million |
Rs-17.21 Million ≈ $-186.10K |
0.003x | -99.43% |
| 2016-03-31 | Rs-2.45 Billion ≈ $-26.54 Million |
Rs-1.19 Billion ≈ $-12.92 Million |
0.487x | +122.46% |
| 2015-03-31 | Rs-395.00 Million ≈ $-4.27 Million |
Rs855.75 Million ≈ $9.25 Million |
-2.166x | -328.56% |
| 2014-03-31 | Rs1.08 Billion ≈ $11.72 Million |
Rs1.03 Billion ≈ $11.11 Million |
0.948x | +240.79% |
| 2013-03-31 | Rs2.17 Billion ≈ $23.50 Million |
Rs-1.46 Billion ≈ $-15.82 Million |
-0.673x | -470.93% |
| 2011-03-31 | Rs3.30 Billion ≈ $35.67 Million |
Rs598.64 Million ≈ $6.47 Million |
0.182x | +9122.60% |
| 2010-03-31 | Rs2.80 Billion ≈ $30.26 Million |
Rs-5.63 Million ≈ $-60.88K |
-0.002x | -100.95% |
| 2009-03-31 | Rs2.42 Billion ≈ $26.12 Million |
Rs509.22 Million ≈ $5.51 Million |
0.211x | +76.03% |
| 2008-03-31 | Rs1.78 Billion ≈ $19.27 Million |
Rs213.43 Million ≈ $2.31 Million |
0.120x | +316.53% |
| 2007-03-31 | Rs1.49 Billion ≈ $16.09 Million |
Rs-82.28 Million ≈ $-889.78K |
-0.055x | -206.94% |
| 2006-03-31 | Rs1.30 Billion ≈ $14.03 Million |
Rs67.09 Million ≈ $725.56K |
0.052x | -- |
About Ind-Swift Limited
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin… Read more